Vincentius-Diakonissen-Kliniken gAG
- Address
- lock Available on a paid plan
Neoplasms Research at Vincentius-Diakonissen-Kliniken gAG
Clinical studies at this Karlsruhe hospital focus on cancer care, with research aimed at improving first-line treatment options and better understanding how immunotherapy can be used in everyday practice.
- Classical Hodgkin lymphoma research is exploring more personalized treatment approaches for patients with early-stage unfavorable disease.
- Non-small cell lung cancer studies are assessing new combination strategies for previously untreated advanced non-squamous NSCLC.
- Key goals include evaluating how well these treatments work and how well they are tolerated in real patients.
The site’s work in oncology reflects a strong interest in both improving outcomes and refining treatment selection through checkpoint inhibition and other modern cancer therapies.
Clinical Trial Focus in Medizinische Klinik 2 Karlsruhe
This research program centers on malignant neoplasms, with trials designed to test innovative treatment combinations and support more individualized care for patients with two distinct cancers.
- Early-stage unfavorable classical Hodgkin lymphoma: studying an individualized approach to first-line therapy.
- Advanced non-squamous non-small cell lung cancer: evaluating a new immunotherapy-based combination against an established comparator regimen.
- Both trials are focused on measuring treatment effectiveness and longer-term disease control.
With a small but targeted portfolio, the site contributes to research that may help shape future standards in cancer treatment and patient-tailored therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 58 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1University Of Cologne1active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1University Of Cologne3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vincentius-Diakonissen-Kliniken gAG
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in Patients with previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer | F. Hoffmann-La Roche AG | Phase IV | Not Recruiting | Dec 2020 | Aug 2025 |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2019-02-13 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.